-
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data
Wednesday, September 28, 2022 - 6:09am | 398Read More...Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd. (OTC: ESALY) announced late on Tuesday positive Phase 3 results for their second-generation Alzheimer's treatment candidate lecanemab. What Happened: Biogen-Eisai’s late-stage trial would provide “strongly...
-
Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock
Wednesday, September 28, 2022 - 12:35am | 531Read More...Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate. What Happened: Biogen and Eisai said the global Phase 3 confirmatory study, "Clarity...
